Co-inhibition of MPS-1 with BCL-2 family inhibitors enhances lung cancer cell killing in 2D and 3D culture systems

Authors

  • B. Pinto Unidade de Investigação em Patologia e Reabilitação Oral (UNIPRO), Instituto Universitário de Ciências da Saúde (IUCS), CESPU, Rua Central de Gandra 1317, 4585-116, Gandra, Portugal; Universidade Federal de Minas Gerais (UFMG), Instituto de Ciências Biológicas, Departamento de Fisiologia e Biofísica, Av. Pres. Antônio Carlos 6627, 31270-901, Belo Horizonte, Brasil https://orcid.org/0000-0002-8804-6104
  • P. Silva Unidade de Investigação em Patologia e Reabilitação Oral (UNIPRO), Instituto Universitário de Ciências da Saúde (IUCS), CESPU, Rua Central de Gandra 1317, 4585-116, Gandra, Portugal; Unidade de Investigação em Toxicologia (TOXRUN), Instituto Universitário de Ciências da Saúde (IUCS), CESPU, Rua Central de Gandra, 1317, 4585-116, Gandra, Portugal
  • B. Sarmento i3S – Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Rua Alfredo Allen 208, 4200-135, Porto, Portugal
  • J. Carvalho-Tavares Universidade Federal de Minas Gerais (UFMG), Instituto de Ciências Biológicas, Departamento de Fisiologia e Biofísica, Av. Pres. Antônio Carlos 6627, 31270-901, Belo Horizonte, Brasil
  • Hassan Bousbaa Unidade de Investigação em Patologia e Reabilitação Oral (UNIPRO), Instituto Universitário de Ciências da Saúde (IUCS), CESPU, Rua Central de Gandra 1317, 4585-116, Gandra, Portugal https://orcid.org/0000-0002-4006-5779

DOI:

https://doi.org/10.48797/sl.2023.24

Keywords:

Poster

Abstract

Background: Lung cancer is the leading cause of cancer death worldwide, posing a significant public health challenge [1]. Currently available therapies, when administered as monotherapy, have limited efficacy, high toxicity, and can lead to increased tumor resistance. Overexpression of MPS-1, a protein kinase involved in mitosis, has been observed in various types of tumors. Its inhibition is associated with aberrant chromosome segregation, leading to cell death. Also, overexpression of anti-apoptotic proteins from the BCL-2 family has been reported in different cancer types, and inhibiting them can enhance cancer cell killing [2,3]; Objective: To assess the antitumor potential of combining a MPS-1 inhibitor with a BCL- 2 family inhibitor, in both 2D and 3D lung cancer cells (A549); Methods: MPS-1 mRNA and protein levels were assessed by qRT-PCR and western blot, respectively. In 2D cultures, the compounds cytotoxic activity was evaluated by MTT assay. The effects of the combination (antagonistic/additive/synergistic effects) were determined using the Combenefit software. The cell death was evaluated by TUNEL method and by flow cytometry (annexin V/propidium iodide). To assess the antiproliferative activity, the colony formation assay was performed. In 3D cultures, spheroid viability and apoptosis were determined by CellTiter-Glo assay and annexin V/ propidium iodide labeling, respectively; Results: Our results demonstrated that MPS-1 mRNA and protein levels were increased in A549 cells. Co-treatment of 2D cultures with the MPS-1 inhibitor and the BCL- 2 family inhibitor resulted in various synergistic points. The combination with the lowest pharmacological concentrations inhibited cancer cell proliferation, and induced cell death by apoptosis. The results were confirmed in a 3D spheroid model. Conclusions: Cancer cell killing activity of the MPS-1 inhibitor is enhanced when combined with the BCL- 2 family inhibitor, both in 2D and 3D cultures.

References

1. Duma, N.; Santana-Davila, R.; Molina, J. R., Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment. Mayo Clinic proceedings 2019, 94 (8), 1623-1640.

2. Henriques, A. C.; Ribeiro, D.; Pedrosa, J.; Sarmento, B.; Silva, P. M. A.; Bousbaa, H., Mitosis inhibitors in anticancer therapy: When blocking the exit becomes a solution. Cancer letters 2019, 440-441, 64-81.

3. Pinto, B.; Novais, P.; Henriques, A. C.; Carvalho-Tavares, J.; Silva, P. M. A.; Bousbaa, H., Navitoclax Enhances the Therapeutic Effects of PLK1 Targeting on Lung Cancer Cells in 2D and 3D Culture Systems. Pharmaceutics 2022, 14 (6).

Downloads

Published

2023-04-21

How to Cite

Pinto, B., Silva, P., Sarmento, B., Carvalho-Tavares, J., & Bousbaa, H. (2023). Co-inhibition of MPS-1 with BCL-2 family inhibitors enhances lung cancer cell killing in 2D and 3D culture systems. Scientific Letters, 1(Sup 1). https://doi.org/10.48797/sl.2023.24

Issue

Section

Posters

Most read articles by the same author(s)

Similar Articles

1 2 3 4 5 6 7 > >> 

You may also start an advanced similarity search for this article.